Ori-Genic Biotech Corporation
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Pilatus Biosciences offers a unique opportunity to invest early at an attractive valuation. Our innovative therapies are already drawing strong interest from global pharmaceutical leaders, positioning us for high-value licensing deals or early M&A exits.
The content above was translated by Ai
Founded Year
2021
Unified Business No.
91118204
Status
Active
Number of Employees
0
Total Paid-in
Capital
30,000,000 (NT$)
Location of Company
Taiwan
, Tainan City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Pilatus Biosciences, founded in 2022, pioneers first-in-class biologics targeting metabolic checkpoints to advance cancer immunotherapy. Drawing on groundbreaking research from the Ludwig Institute for Cancer Research (LICR) and the University of Lausanne
The content above was translated by Ai
